Publications by: Megan Lyle
Up a level |
Weppler, Alison M., Da Meda, Laetitia, Pires da Silva, Ines, Xu, Wen, Grignani, Giovanni, Menzies, Alexander M., Carlino, Matteo S., Long, Georgina V., Lo, Serigne N., Nordman, Ina, Steer, Christopher B., Lyle, Megan, Trojaniello, Claudia, Ascierto, Paolo A., Lebbe, Celeste, and Sandhu, Shahneen (2023) Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. European Journal of Cancer, 183. pp. 109-118.
Pires da Silva, Ines, Ahmed, Tasnia, Reijers, Irene L.M., Weppler, Alison M., Betof Warner, Allison, Patrinely, James Randall, Serra-Bellver, Patricio, Allayous, Clara, Mangana, Joanna, Nguyen, Khang, Zimmer, Lisa, Trojaniello, Claudia, Stout, Dan, Lyle, Megan, Klein, Oliver, Gerard, Camille L., Michielin, Olivier, Haydon, Andrew, Ascierto, Paolo A., Carlino, Matteo S., Lebbe, Celeste, Lorigan, Paul, Johnson, Douglas B., Sandhu, Shahneen, Lo, Serigne N., Blank, Christian U., Menzies, Alexander M., and Long, Georgina V. (2021) Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. The Lancet Oncology, 22 (6). pp. 836-847.